Structure via PubChem · Public domain (PubChem)
alectinib
Sign in to saveAlso known as AF802, Alecensa®, CH5424802, CH 5424802, AF-802, AF 802, Alecensa, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
Key facts
- Drug.DrugBank
- DB11363
- Drug.image
- Alectinib structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.JAN
- alectinib hydrochloride
- Drug.tradename
- Alecensa
- Drug.MedlinePlus
- a616007
- Drug.DailyMedID
- Alectinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- ED03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 37% (under fed conditions)
via Wikipedia infobox
Chemical data
- Formula
- C30H34N4O2
- Molecular weight
- 482.6 g/mol
- IUPAC name
- 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- SMILES
- CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C
- InChIKey
- KDGFLJKFZUIJMX-UHFFFAOYSA-N
- XLogP
- 5.2
- Polar surface area
- 72.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2015
- Admin. routes
- oral
- Indications
- non-small cell lung carcinoma, liver disease, neoplasm, glioblastoma multiforme
via ChEMBL · EBI
Research
1,489 papers- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.The New England journal of medicine · 2024
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.The New England journal of medicine · 2017
- Alectinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2018
- Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.Lancet (London, England) · 2017
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 482.268
Show 6 more facts
- medical condition treated
- non-small-cell lung carcinoma
- canonical SMILES
- CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6
- World Health Organisation international non-proprietary name
- alectinib
- chemical formula
- C₃₀H₃₄N₄O₂
- Commons category
- Alectinib
- subject has role
- protein kinase inhibitors
Sources (7)
via Wikidata · CC0
~7 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- References
- External links
Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
The most common side effects include constipation, muscle pain and edema (swelling) including of the ankles and feet, the face, the eyelids and the area around the eyes.
Excerpted from Wikipedia’s “alectinib” article, available under the CC BY-SA 4.0 licence.